Phase 3 Conjunctival Allergen Challenge Trial of NTa53

Phase 3 Allergen Challenge Trial of NTa53 in Patients with Allergic Conjunctivitis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031240351

Enrollment

Registered

2024-09-26

Start date

2024-10-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Conjunctivitis

Interventions

NTa53, active drug and placebo administration, and allergen challenge

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Provided signed, written informed consent. -Has a positive result from a Type I allergy test.

Exclusion criteria

Exclusion criteria: -Eye disease other than allergic conjunctivitis is present and requires treatment. -Other protocol-specified exclusion criteria may apply.

Design outcomes

Primary

Measure	Time frame
Efficacy (Ocular Itching Score and Conjunctival Redness Score)	—

Contacts

Public ContactTakeshi Yonemichi

Nitto Medic Co., Ltd.

clinical@nittomedic.co.jp+81-76-455-3541

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026